A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection

Jia-Horng Kao, Rong-Nan Chien, Ting-Tsung Chang, Cheng-Yuan Peng, Tsung-Hui Hu, Gin-Ho Lo, Horng-Yuan Wang, Jyh-Jou Chen, Jenny C Yang, Steven J Knox, Lingling Han, Hongmei Mo, Anita Mathias, Diana M Brainard, I-Shyan Sheen, Yu-Chun Hsu, Chi-Jen Chu, Wan-Long Chuang, Jia-Horng Kao, Rong-Nan Chien, Ting-Tsung Chang, Cheng-Yuan Peng, Tsung-Hui Hu, Gin-Ho Lo, Horng-Yuan Wang, Jyh-Jou Chen, Jenny C Yang, Steven J Knox, Lingling Han, Hongmei Mo, Anita Mathias, Diana M Brainard, I-Shyan Sheen, Yu-Chun Hsu, Chi-Jen Chu, Wan-Long Chuang

Abstract

Background & aims: In Taiwan, patients with chronic hepatitis C virus (HCV) infection are currently treated with pegylated interferon-alpha plus ribavirin, but interferon-based regimens can be poorly tolerated, especially by those with advanced liver disease and the elderly. Sofosbuvir, an oral nucleotide analogue inhibitor of HCV NS5B polymerase, is approved in Europe, the USA and Japan for treating chronic HCV infection. This phase 3b study examined the efficacy and safety of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 HCV infection ± compensated cirrhosis.

Methods: In this multicentre, open-label, phase 3b (NCT02021643) study, 87 patients (n = 43, treatment-naive; n = 44, treatment-experienced) received 12 weeks of treatment with sofosbuvir plus weight-based ribavirin. The primary efficacy endpoint was the proportion of patients with sustained virological response 12 weeks after treatment discontinuation (SVR12). Safety and pharmacokinetic data were also collected.

Results: All 87 patients (100%; 95% confidence interval, 92-100%) achieved SVR12, including the 13 patients with compensated cirrhosis. The most common treatment-emergent adverse events (AEs) were insomnia (16%, 14/87) and upper respiratory tract infection (16%, 14/87). No grade 3 or grade 4 AE was reported. There was one serious AE (biliary colic), which was deemed unrelated to study treatment. Laboratory abnormalities other than ribavirin-related reductions in haemoglobin were uncommon.

Conclusions: The results from this phase 3b study demonstrate that 12 weeks of treatment with the interferon-free regimen sofosbuvir plus ribavirin is effective and well tolerated in both treatment-naive and treatment-experienced Taiwanese patients with chronic genotype 2 HCV infection.

Keywords: Taiwan; genotype 2; hepatitis C virus (HCV); ribavirin; sofosbuvir.

© 2016 The Authors. Liver International Published by John Wiley & Sons Ltd.

References

    1. McEwan P, Ward T, Chen C‐J, et al Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection. Value Health 2014; 3: 5–11.
    1. Lee MH, Yang HI, Lu SN, et al Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long‐term predictors from a community‐based cohort study. J Clin Oncol 2010; 28: 4587–93.
    1. Lee MH, Yang HI, Lu SN, et al Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community‐based long‐term prospective study. J Infect Dis 2012; 206: 469–77.
    1. Yu ML, Chuang WL, Chen SC, et al Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. J Med Virol 2001; 65: 58–65.
    1. Omata M, Kanda T, Yu M‐L, et al APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012; 6: 409–35.
    1. Yu ML, Dai CY, Lin ZY, et al A randomized trial of 24‐ vs. 48‐week courses of PEG interferon alpha‐2b plus ribavirin for genotype‐1b‐infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006; 26: 73–81.
    1. Yu ML, Dai CY, Huang JF, et al A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553–9.
    1. Huang CF, Yang JF, Dai CY, et al Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010; 201: 751–9.
    1. Hu CC, Lin CL, Kuo YL, et al Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Aliment Pharmacol Ther 2013; 37: 81–90.
    1. Gilead Sciences International Ltd . SOVALDI (sofosbuvir) Summary of Product Characteristics. Carrigtohill, Ireland: Gilead Sciences International Ltd., 2015.
    1. Gilead Sciences Inc . SOVALDI (sofosbuvir) Prescribing Information. Foster City, CA: Gilead Sciences, Inc., 2014.
    1. Omata M, Nishiguchi S, Ueno Y, et al Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open‐label, phase 3 trial. J Viral Hepat 2014; 21: 762–8.
    1. Lawitz E, Mangia A, Wyles D, et al Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878–87.
    1. Jacobson IM, Gordon SC, Kowdley KV, et al Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867–77.
    1. Zeuzem S, Dusheiko GM, Salupere R, et al Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993–2001.
    1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.
    1. Ahn SH, Lim Y‐S, Lee K‐S, et al A phase 3b study of sofosbuvir plus ribavirin in treatment‐naïve and treatment‐experienced Korean patients chronically infected with genotype 2 Hepatitis C virus. J Viral Hepat 2016; 23: 358–65.
    1. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404–13.
    1. García‐Samaniego J, Romero M, Granados R, et al Factors associated with early virological response to peginterferon‐α‐2a/ribavirin in chronic hepatitis C. World J Gastroenterol 2013; 19: 1943–52.
    1. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639–44.
    1. Chen JY, Lin CY, Wang CM, et al IL28B genetic variations are associated with high sustained virological response (SVR) of interferon‐α plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun 2011; 12: 300–9.
    1. Hsu CS, Hsu SJ, Chen HC, et al Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci USA 2011; 108: 3719–24.
    1. Ge D, Fellay J, Thompson AJ, et al Genetic variation in IL28B predicts hepatitis C treatment‐induced viral clearance. Nature 2009; 461: 399–401.
    1. Thomas DL, Thio CL, Martin MP, et al Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798–801.
    1. Foster GR, Pianko S, Brown A, et al Efficacy of sofosbuvir plus ribavirin with or without peginterferon‐alfa in patients with hepatitis C virus genotype 3 infection and treatment‐experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015; 149: 1462–70.
    1. Genentech . Ribavirin (COPEGUS) Prescribing Information. South San Francisco, CA: Genentech USA, Inc., 2013.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere